Tumors lacking hormone receptors and HER2 are defined as triple-negative breast cancer (TNBC), the prevalence of TNBC varies across countries from 6.8% of all breast cancers in The Netherlands to 27.9% in India [2]. This evidence concerns the gene ERBB2 and breast cancer.